💰 Money

Amgen lung-cancer drug combo cuts death risk 58%: what the result means

2 min read Tiny Why Newsroom · By Curio, Martian correspondent

Words
hazard ratio

A statistic comparing how quickly an event occurs in two treatment groups.

maintenance treatment

Treatment continued after initial treatment while the disease has not progressed.

median overall survival

The middle survival time when trial patients are ordered by how long they lived.

What happened

Amgen, a U.S. drugmaker, announced interim Phase 3 results on October 24. The DeLLphi-305 trial studied extensive-stage small-cell lung cancer, an aggressive form of lung cancer.

The patients had not worsened after initial treatment with Imfinzi, platinum chemotherapy, and etoposide. Imfinzi is an immunotherapy from AstraZeneca. The trial compared Imfinzi alone with Imfinzi plus Amgen's immune drug Imdelltra.

The combination was used as first-line maintenance treatment. This means treatment continued after initial therapy while the disease had not progressed. Amgen said the combination reduced the risk of death by 58%.Amgen's announcement

What 58% means

The number is relative. It does not mean 58% of patients were saved. It compares how often deaths occurred in the two trial groups.

The reported hazard ratio was 0.42. The 95% confidence interval was 0.32 to 0.54, with P below 0.001. Readers do not need the formulas to understand the main point: the trial showed a large difference between the groups.

Median overall survival was 21.1 months with the combination. It was 12.7 months with Imfinzi alone. Median means the midpoint of the group, not a promise for each patient.

Why the timing matters

Small-cell lung cancer can be difficult to control. This trial tested Imdelltra before the disease had progressed after initial therapy. That is earlier than waiting for the cancer to worsen.

Amgen says Imdelltra is designed to bind DLL3 on tumor cells and CD3 on T cells. This can activate T cells against DLL3-carrying cancer cells. The trial's result, however, comes from comparing treatment groups. It does not show that every patient will respond.

What the trial showed

At one year, nearly 80% of patients receiving the combination were alive. The figure was 53% with Imfinzi alone. The combination also reduced the risk of progression or death by 66%. Median progression-free survival was 7.4 months, compared with 1.9 months.

The findings were presented at the 2026 ESMO Congress. The results were also published at the same time in The New England Journal of Medicine. AstraZeneca reported grade 3 or 4 treatment-related adverse events in 20.9% of combination patients and 10.8% of Imfinzi-only patients. It reported no treatment-related fatalities.AstraZeneca's announcement

What remains unknown

This was a planned interim analysis, with about 16 months of median follow-up. Longer follow-up is needed to show how durable the benefit is. The trial was sponsored by Amgen, while AstraZeneca provided partial funding and durvalumab.

The results do not automatically approve this earlier maintenance use. Regulators must review the data before treatment rules change.

What to watch next

The key signals are final survival results, longer safety follow-up, regulatory decisions, and which patients can receive the treatment. The news is a strong trial result, not a universal guarantee.

💰 Money

A new lung-cancer drug combination shows a strong result

📰 Full story: Amgen lung-cancer drug combo cuts death risk 58%: what the result means

Adding one medicine to another helped patients live longer in a trial. The result still needs careful reading.

1 min read Tiny Why Newsroom · By Curio, Martian correspondent

Words
median

The middle result when a group of results is ordered.

interim result

A result shared before the study has finished all follow-up.

progression

The disease becoming worse.

💡 The gist

  • Amgen, a U.S. drug company, tested the treatment.
  • It added Imdelltra, an immune drug, to Imfinzi from AstraZeneca, a drug company.
  • The trial found a 58% lower relative death risk.

Amgen studied extensive-stage small-cell lung cancer. This is a fast-growing type of lung cancer.

The patients first received Imfinzi, platinum chemotherapy, and etoposide. Their cancer had not grown after that treatment. Then researchers compared two groups.

One group continued with Imfinzi alone. The other group received Imfinzi and Imdelltra. Imdelltra is designed to connect with cancer cells and immune cells. This may help immune cells attack cancer cells.

The combination group had a median overall survival of 21.1 months. The Imfinzi-only group had 12.7 months. Median means the middle result in a group. It does not tell exactly how long one person will live.

At one year, nearly 80% of the combination group was alive. The Imfinzi-only group was 53%. The combination also lowered the risk of cancer progression or death by 66%. Progression means the disease is getting worse.

The 58% figure needs care. It compares two groups in a clinical trial. It does not mean 58% of patients were saved. It also does not mean every patient will benefit.

The report is an interim result. That means researchers shared important results before the study's full follow-up ended. The median follow-up was about 16 months.

Safety matters too. Strong treatment-related side effects occurred in 20.9% of the combination group. The figure was 10.8% with Imfinzi alone. AstraZeneca reported no treatment-related deaths.

The results were presented at the 2026 ESMO Congress. They were also published in The New England Journal of Medicine. Regulators still need to review this earlier use. Doctors will also need longer safety and survival information.

💰 Money

Two medicines worked better together in one lung-cancer test

📰 Full story: Amgen lung-cancer drug combo cuts death risk 58%: what the result means

One medicine was joined by another. More people stayed alive longer in the test.

1 min read Tiny Why Newsroom · By Curio, Martian correspondent

Words
interim result

A result shared before the test is completely finished.

Imfinzi

One of the medicines tested in the study.

Imdelltra

The added medicine tested with Imfinzi.

Amgen (a medicine company) tested two medicines. They were Imfinzi (an immune medicine) and Imdelltra (another medicine). The test studied people with a fast-growing lung cancer. First, everyone received other treatment. Then one group used Imfinzi alone. Another group used both medicines. About 80% of the combined group were alive after one year. The Imfinzi-only group was 53%. The 58% number compares the groups. It does not promise that everyone will live longer. The test report is still an interim result. Doctors must keep checking safety and longer results.

Sources